China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Intrinsic Value
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. [ Read More ]
The intrinsic value of one China Resources Boya Bio pharmaceutical Group Co Ltd stock under the Base Case scenario is 27.45 CNY. Compared to the current market price of 27.78 CNY, China Resources Boya Bio pharmaceutical Group Co Ltd is Overvalued by 1%.
Valuation Backtest
China Resources Boya Bio pharmaceutical Group Co Ltd
Run backtest to discover the historical profit from buying and selling China Resources Boya Bio pharmaceutical Group Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of China Resources Boya Bio pharmaceutical Group Co Ltd's business.
What risks and challenges
does China Resources Boya Bio pharmaceutical Group Co Ltd face in the near future?
Summarize the latest earnings report
of China Resources Boya Bio pharmaceutical Group Co Ltd.
Provide P/E
for China Resources Boya Bio pharmaceutical Group Co Ltd and its competitors.
Balance Sheet Decomposition
China Resources Boya Bio pharmaceutical Group Co Ltd
Current Assets | 6.4B |
Cash & Short-Term Investments | 5.1B |
Receivables | 685.9m |
Other Current Assets | 583.8m |
Non-Current Assets | 1.8B |
Long-Term Investments | 112.5m |
PP&E | 711.8m |
Intangibles | 866m |
Other Non-Current Assets | 113.3m |
Current Liabilities | 556.3m |
Accounts Payable | 102.9m |
Accrued Liabilities | 89.6m |
Short-Term Debt | 38m |
Other Current Liabilities | 325.7m |
Non-Current Liabilities | 75m |
Long-Term Debt | 23.8m |
Other Non-Current Liabilities | 51.2m |
Earnings Waterfall
China Resources Boya Bio pharmaceutical Group Co Ltd
Revenue
|
2.9B
CNY
|
Cost of Revenue
|
-1.4B
CNY
|
Gross Profit
|
1.4B
CNY
|
Operating Expenses
|
-954m
CNY
|
Operating Income
|
482.2m
CNY
|
Other Expenses
|
-4.2m
CNY
|
Net Income
|
478m
CNY
|
Free Cash Flow Analysis
China Resources Boya Bio pharmaceutical Group Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
China Resources Boya Bio pharmaceutical Group Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
China Resources Boya Bio pharmaceutical Group Co Ltd's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
China Resources Boya Bio pharmaceutical Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
China Resources Boya Bio pharmaceutical Group Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
China Resources Boya Bio pharmaceutical Group Co Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Boya Bio pharmaceutical Group Co Ltd is 35.96 CNY with a low forecast of 31.08 CNY and a high forecast of 40.95 CNY.
Shareholder Return
Price
China Resources Boya Bio pharmaceutical Group Co Ltd
Average Annual Return | 6.51% |
Standard Deviation of Annual Returns | 4.74% |
Max Drawdown | -59% |
Market Capitalization | 14B CNY |
Shares Outstanding | 504 248 738 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one China Resources Boya Bio pharmaceutical Group Co Ltd stock under the Base Case scenario is 27.45 CNY.
Compared to the current market price of 27.78 CNY, China Resources Boya Bio pharmaceutical Group Co Ltd is Overvalued by 1%.